Structural biology and evolution of the TGF-β family

Cold Spring Harbor Perspectives in Biology

Volumn 8, Issue 12, 2016, Pages

  Hinck, Andrew P ^a   Mueller, Thomas D ^b   Springer, Timothy A ^c,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; GENETICS; HUMAN; MOLECULAR EVOLUTION; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; EVOLUTION, MOLECULAR; HUMANS; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID; TRANSFORMING GROWTH FACTOR BETA;

EID: 85006077914     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a022103     Document Type: Article

References (243)

1. Adamska M, Degnan SM, Green KM, Adamski M, Craigie A, Larroux C, Degnan BM. 2007. Wnt and TGF-_ expression in the sponge Amphimedon queenslandica and the origin of metazoan embryonic patterning. PLoS ONE 2: e1031.
2. Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, et al. 2003. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest 112: 575-587
3. Akiyama T, Marques G, Wharton KA. 2012. A large bioactive BMP ligand with distinct signaling properties is produced by alternative proconvertase processing. Sci Signal 5: ra28.
4. Allendorph GP, Vale WW, Choe S. 2006. Structure of the ternary signaling complex of a TGF-β superfamily member. Proc Natl Acad Sci 103: 7643-7648
5. Allendorph GP, Isaacs MJ, Kawakami Y, Izpisua Belmonte JC, Choe S. 2007. BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors. Biochemistry 46: 12238-12247
6. Alt A, Miguel-Romero L, Donderis J, Aristorena M, Blanco FJ, Round A, Rubio V, Bernabeu C, Marina A. 2012. Structural and functional insights into endoglin ligand recognition and binding. PLoS ONE 7: e29948.
7. Ambrosio AL, Taelman VF, Lee HX, Metzinger CA, Coffinier C, De Robertis EM. 2008. Crossveinless-2 Is a BMP feedback inhibitor that binds chordin/BMP to regulate Xenopus embryonic patterning. Dev Cell 15: 248-260
8. Amthor H, Christ B, Rashid-Doubell F, Kemp CF, Lang E, Patel K. 2002. Follistatin regulates bone morphogenetic protein-7 (BMP-7) activity to stimulate embryonic muscle growth. Dev Biol 243: 115-127
9. Amthor H, Nicholas G, McKinnell I, Kemp CF, Sharma M, Kambadur R, Patel K. 2004. Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis. Dev Biol 270: 19-30
10. Anderson SB, Goldberg AL, Whitman M. 2008. Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. J Biol Chem 283: 7027-7035
11. Annes JP, Chen Y, Munger JS, Rifkin DB. 2004. Integrin aVb6-mediated activation of latent TGF-β requires the latent TGF-β binding protein-1. J Cell Biol 165: 723-734
12. Aono A, Hazama M, Notoya K, Taketomi S, Yamasaki H, Tsukuda R, Sasaki S, Fujisawa Y. 1995. Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem Biophys Res Commun 210: 670-677
13. Ardelean DS, Letarte M. 2015. Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia. Front Genet 6: 35.
14. Ashe HL, Levine M. 1999. Local inhibition and long-range enhancement of Dpp signal transduction by Sog. Nature 398: 427-431
15. Baardsnes J, Hinck CS, Hinck AP, O’Connor-McCourt MD. 2009. TbR-II discriminates the high-and low-affinity TGF-β isoforms via two hydrogen-bonded ion pairs. Biochemistry 48: 2146-2155
16. Baarends WM, van Helmond MJ, Post M, van der Schoot PJ, Hoogerbrugge JW, deWinter JP, Uilenbroek JT, Karels B, Wilming LG, Meijers JH, et al. 1994. A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the mullerian duct. Development 120: 189-197
17. Babitt JL, Zhang Y, Samad TA, Xia Y, Tang J, Campagna JA, Schneyer AL, Woolf CJ, Lin HY. 2005. Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor. J Biol Chem 280: 29820-29827
18. Bell E, Munoz-Sanjuan I, Altmann CR, Vonica A, Brivanlou AH. 2003. Cell fate specification and competence by Coco, a maternal BMP, TGFb and Wnt inhibitor. Development 130: 1381-1389
19. Bell CH, Healey E, van Erp S, Bishop B, Tang C, Gilbert RJ, Aricescu AR, Pasterkamp RJ, Siebold C. 2013. Structure of the repulsive guidance molecule (RGM)-neogenin signaling hub. Science 341: 77-80
20. Belville C, Van Vlijmen H, Ehrenfels C, Pepinsky B, Rezaie AR, Picard JY, Josso N, di Clemente N, Cate RL. 2004. Mutations of the anti-mullerian hormone gene in patients with persistent mullerian duct syndrome: Biosynthesis, secretion, and processing of the abnormal proteins and analysis using a three-dimensional model. Mol Endocrinol 18: 708-721
21. Blair JE, Hedges SB. 2005. Molecular phylogeny and divergence times of deuterostome animals. Mol Biol Evol 22: 2275-2284
22. Blanchet MH, Le Good JA, Mesnard D, Oorschot V, Baflast S, Minchiotti G, Klumperman J, Constam DB. 2008. Cripto recruits Furin and PACE4 and controls Nodal trafficking during proteolytic maturation. EMBO J 27: 2580-2591
23. Bocharov EV, Blommers MJ, Kuhla J, Arvinte T, Burgi R, Arseniev AS. 2000. Sequence-specific 1H and 15Nassignment and secondary structure of transforming growth factor b3. J Biomol NMR 16: 179-180
24. Bocharov EV, Korzhnev DM, Blommers MJ, Arvinte T, Orekhov VY, Billeter M, Arseniev AS. 2002. Dynamics-modulated biological activity of transforming growth factor b3. J Biol Chem 277: 46273-46279
25. Boesen CC, Radaev S, Motyka SA, Patamawenu A, Sun PD. 2002. The 1.1Å crystal structure of human TGF-β type II receptor ligand binding domain. Structure 10: 913-919
26. Bork P. 1993. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 327: 125-130
27. Bork P, Sander C. 1992. A large domain common to sperm receptors (Zp2 and Zp3) and TGF-β type III receptor. FEBS Lett 300: 237-240
28. Boschert V, van Dinther M, Weidauer S, van Pee K, Muth EM, Ten Dijke P, Mueller TD. 2013.Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition. PLoS ONE 8: e81710.
29. Bourhis E, Wang W, Tam C, Hwang J, Zhang Y, Spittler D, Huang OW, Gong Y, Estevez A, Zilberleyb I, et al. 2011. Wnt antagonists bind through a short peptide to the first b-propeller domain of LRP5/6. Structure 19: 1433-1442
30. Bradshaw AD. 2012. Diverse biological functions of the SPARC family of proteins. Int J Biochem Cell Biol 44: 480-488
31. Brown MA, Zhao Q, Baker KA, Naik C, Chen C, Pukac L, Singh M, Tsareva T, Parice Y, Mahoney A, et al. 2005. Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem 280: 25111-25118.
32. Brunet LJ, McMahon JA, McMahon AP, Harland RM. 1998. Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science 280: 1455-1457
33. Buijs JT, van der Horst G, van den Hoogen C, Cheung H, de Rooij B, Kroon J, Petersen M, van Overveld PG, Pelger RC, van der Pluijm G. 2012. The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation. Oncogene 31: 2164-2174.
34. Calvanese L, Saporito A, Marasco D, D’Auria G, Minchiotti G, Pedone C, Paolillo L, Falcigno L, Ruvo M. 2006. Solution structure of mouse Cripto CFC domain and its inactive variant Trp107Ala. J Med Chem 49: 7054-7062
35. Camus LM, Lambert LA. 2007. Molecular evolution of hemojuvelin and the repulsive guidance molecule family. J Mol Evol 65: 68-81
36. Cash JN, Rejon CA, McPherron AC, Bernard DJ, Thompson TB. 2009. The structure of myostatin:follistatin 288: Insights into receptor utilization and heparin binding. EMBO J 28: 2662-2676
37. Cash JN, Angerman EB, Kattamuri C, Nolan K, Zhao H, Sidis Y, Keutmann HT, Thompson TB. 2012. Structure of myostatin follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding. J Biol Chem 287: 1043-1053
38. Castonguay R, Werner ED, Matthews RG, Presman E, Mulivor AW, Solban N, Sako D, Pearsall RS, Underwood KW, Seehra J, et al. 2011. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 286: 30034-30046
39. Chang C, Holtzman DA, Chau S, Chickering T, Woolf EA, Holmgren LM, Bodorova J, Gearing DP, Holmes WE, Brivanlou AH. 2001. Twisted gastrulation can function as a BMP antagonist. Nature 410: 483-487
40. Chang TH, Hsieh FL, Zebisch M, Harlos K, Elegheert J, Jones EY. 2015. Structure and functional properties of Norrin mimic Wnt for signalling with Frizzled4, Lrp5/6, and proteoglycan. eLife 4: doi: 10.7554/eLife.06554.
41. Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP, Wang XF, Lefkowitz RJ, Blobe GC. 2003. b-arrestin 2 mediates endocytosis of type III TGF-β receptor and down-regulation of its signaling. Science 301: 1394-1397.
42. Chen C, Ware SM, Sato A, Houston-Hawkins DE, Habas R, Matzuk MM, Shen MM, Brown CW. 2006. The Vg1-related protein Gdf3 acts in a Nodal signaling pathway in the pre-gastrulation mouse embryo. Development 133: 319-329
43. Chen H, Brady Ridgway J, Sai T, Lai J, Warming S, Chen H, Roose-Girma M, Zhang G, Shou W, Yan M. 2013. Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development. Proc Natl Acad Sci 110: 11887-11892
44. Cheng SK, Olale F, Bennett JT, Brivanlou AH, Schier AF. 2003. EGF-CFC proteins are essential coreceptors for the TGF-β signals Vg1 and GDF1. Genes Dev 17: 31-36
45. Cheng SK, Olale F, Brivanlou AH, Schier AF. 2004. Lefty blocks a subset of TGFb signals by antagonizing EGFCFC coreceptors. PLoS Biol 2: E30.
46. Ciardiello F, Dono R, Kim N, Persico MG, Salomon DS. 1991. Expression of cripto, a novel gene of the epidermal growth factor gene family, leads to in vitro transformation of a normal mouse mammary epithelial cell line. Cancer Res 51: 1051-1054
47. Conley CA, Silburn R, Singer MA, Ralston A, Rohwer-Nutter D, Olson DJ, Gelbart W, Blair SS. 2000. Crossveinless 2 contains cysteine-rich domains and is required for high levels of BMP-like activity during the formation of the cross veins in Drosophila. Development 127: 3947-3959
48. Constam DB. 2014. Regulation of TGFb and related signals by precursor processing. Semin Cell Dev Biol 32: 85-97
49. Cui Y, Hackenmiller R, Berg L, Jean F, Nakayama T, Thomas G, Christian JL. 2001. The activity and signaling range of mature BMP-4 is regulated by sequential cleavage at two sites within the prodomain of the precursor. Genes Dev 15: 2797-2802
50. Daopin S, Piez KA, Ogawa Y, Davies DR. 1992. Crystal structure of transforming growth factor-b 2: An unusual fold for the superfamily. Science 257: 369-373
51. Daopin S, Li M, Davies DR. 1993. Crystal structure of TGFb 2 refined at 1.8 Å resolution. Proteins 17: 176-192
52. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. 2007. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109: 1953-1961
53. David L, Feige JJ, Bailly S. 2009. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev 20: 203-212
54. De Crescenzo G, Hinck CS, Shu Z, Zuniga J, Yang J, Tang Y, Baardsnes J, Mendoza V, Sun L, Lopez-Casillas F, et al. 2006. Three key residues underlie the differential affinity of the TGFb isoforms for the TGFb type II receptor. J Mol Biol 355: 47-62
55. Deep S, Walker KP III, Shu Z, Hinck AP. 2003. Solution structure and backbone dynamics of the TGFb type II receptor extracellular domain. Biochemistry 42: 10126-10139.
56. De Robertis EM, Larrain J, Oelgeschlager M, Wessely O. 2000. The establishment of Spemann’s organizer and patterning of the vertebrate embryo. Nat Rev Genet 1: 171-181.
57. Diestel U, Resch M, Meinhardt K, Weiler S, Hellmann TV, Mueller TD, Nickel J, Eichler J, Muller YA. 2013. Identification of a novel TGF-β-binding site in the zona pellu-cida C-terminal (ZP-C) domain of TGF-β-receptor-3 (TGFR-3). PLoS ONE 8: e67214.
58. Dong X, Hudson E, Lu C, Springer TA. 2014. Structural determinants of integrin b-subunit specificity for latent TGF-β. Nat Struct Mol Biol 21: 1091-1096
59. Dunn CW, Hejnol A, Matus DQ, Pang K, Browne WE, Smith SA, Seaver E, Rouse GW, Obst M, Edgecombe GD, et al. 2008. Broad phylogenomic sampling improves resolution of the animal tree of life. Nature 452: 745-749
60. Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, Lopez-Casillas F. 2001. Ligand binding and functional properties of betaglycan, a coreceptor of the transforming growth factor-b superfamily. Specialized binding regions for transforming growth factor-b and inhibin A. J Biol Chem 276: 14588-14596
61. Esquivies L, Blackler A, Peran M, Rodriguez-Esteban C, Izpisua Belmonte JC, Booker E, Gray PC, Ahn C, Kwiatkowski W, Choe S. 2014. Designer nodal/BMP2 chimeras mimic nodal signaling, promote chondrogenesis, and reveal a BMP2-like structure. J Biol Chem 289: 1788-1797.
62. Feng D, Kim T, Ozkan E, Light M, Torkin R, Teng KK, Hempstead BL, Garcia KC. 2010. Molecular and structural insight into proNGF engagement of p75NTR and sortilin. J Mol Biol 396: 967-984
63. Fiebig JE, Weidauer SE, Qiu LY, Bauer M, Schmieder P, Beerbaum M, Zhang JL, Oschkinat H, Sebald W, Mueller TD. 2013. The clip-segment of the von Willebrand domain 1 of the BMP modulator protein Crossveinless 2 is preformed. Molecules 18: 11658-11682
64. Francois V, Solloway M, O’Neill JW, Emery J, Bier E. 1994. Dorsal-ventral patterning of the Drosophila embryo depends on a putative negative growth factor encoded by the short gastrulation gene. Genes Dev 8: 2602-2616
65. Garcia Abreu J, Coffinier C, Larrain J, Oelgeschlager M, De Robertis EM. 2002. Chordin-like CR domains and the regulation of evolutionarily conserved extracellular signaling systems. Gene 287: 39-47
66. Gentry LE, Nash BW. 1990. The pro domain of pre-protransforming growth factor b1 when independently expressed is a functional binding protein for the mature growth factor. Biochemistry 29: 6851-6857
67. Glinka A, Wu W, Onichtchouk D, Blumenstock C, Niehrs C. 1997. Head induction by simultaneous repression of Bmp and Wnt signalling in Xenopus. Nature 389: 517-519.
68. Glister C, Kemp CF, Knight PG. 2004. Bone morphogenetic protein (BMP) ligands and receptors in bovine ovarian follicle cells: Actions of BMP-4, -6 and-7 on granulosa cells and differential modulation of Smad-1 phosphorylation by follistatin. Reproduction 127: 239-254
69. Gong Y, Krakow D, Marcelino J, Wilkin D, Chitayat D, Babul-Hirji R, Hudgins L, Cremers CW, Cremers FP, Brunner HG, et al. 1999. Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis. Nat Genet 21: 302-304
70. Gougos A, Letarte M. 1990. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265: 8361-8364
71. Gray AM, Mason AJ. 1990. Requirement for activin A and transforming growth factor-b1 pro-regions in homodimer assembly. Science 247: 1328-1330
72. Gray PC, Harrison CA, Vale W. 2003. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci 100: 5193-5198.
73. Greenwald J, Fischer WH, Vale WW, Choe S. 1999. Threefinger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase. Nat Struct Biol 6: 18-22
74. Greenwald J, Groppe J, Gray P, Wiater E, Kwiatkowski W, Vale W, Choe S. 2003. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol Cell 11: 605-617
75. Greenwald J, Vega ME, Allendorph GP, Fischer WH, Vale W, Choe S. 2004. A flexible activin explains the membranedependent cooperative assembly of TGF-β family receptors. Mol Cell 15: 485-489
76. Gregory KE, Ono RN, Charbonneau NL, Kuo CL, Keene DR, Bachinger HP, Sakai LY. 2005. The prodomain of BMP-7 targets the BMP-7 complex to the extracellular matrix. J Biol Chem 280: 27970-27980
77. Griffith DL, Keck PC, Sampath TK, Rueger DC, Carlson WD. 1996. Three-dimensional structure of recombinant human osteogenic protein 1: Structural paradigm for the transforming growth factor b superfamily. ProcNatl Acad Sci 93: 878-883
78. Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, Affolter M, Vale WW, Izpisua Belmonte JC, Choe S. 2002. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420: 636-642
79. Groppe J, Hinck CS, Samavarchi-Tehrani P, Zubieta C, Schuermann JP, Taylor AB, Schwarz PM, Wrana JL, Hinck AP. 2008. Cooperative assembly of TGF-β superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol Cell 29: 157-168
80. Grütter C, Wilkinson T, Turner R, Podichetty S, Finch D, McCourt M, Loning S, Jermutus L, Grutter MG. 2008. A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions. Proc Natl Acad Sci 105: 20251-20256.
81. Guruharsha KG, Rual JF, Zhai B, Mintseris J, Vaidya P, Vaidya N, Beekman C, Wong C, Rhee DY, Cenaj O, et al. 2011. A protein complex network of Drosophila melanogaster. Cell 147: 690-703
82. Hammonds RG Jr, Schwall R, Dudley A, Berkemeier L, Lai C, Lee J, Cunningham N, Reddi AH, Wood WI, Mason AJ. 1991. Bone-inducing activity of mature BMP-2b produced from a hybrid BMP-2a/2b precursor. Mol Endocrinol 5: 149-155
83. Harland RM. 2001. Developmental biology. A twist on embryonic signalling. Nature 410: 423-424
84. Harrington AE, Morris-Triggs SA, Ruotolo BT, Robinson CV, Ohnuma S, Hyvonen M. 2006. Structural basis for the inhibition of activin signalling by follistatin. EMBO J 25: 1035-1045
85. Harrison CA, Al-Musawi SL, Walton KL. 2011. Prodomains regulate the synthesis, extracellular localisation and activity of TGF-β superfamily ligands. Growth Factors 29: 174-186
86. Hart PJ, Deep S, Taylor AB, Shu Z, Hinck CS, Hinck AP. 2002. Crystal structure of the human TbR2 ectodomain-TGF-β3 complex. Nat Struct Biol 9: 203-208
87. Harth S, Kotzsch A, Hu J, Sebald W, Mueller TD. 2010. A selection fit mechanism in BMP receptor IA as a possible source for BMP ligand-receptor promiscuity. PLoS ONE 5: e13049.
88. Hatta T, Konishi H, Katoh E, Natsume T, Ueno N, Kobayashi Y, Yamazaki T. 2000. Identification of the ligand-binding site of the BMP type IA receptor for BMP-4. Biopolymers 55: 399-406
89. Hauburger A, von Einem S, Schwaerzer GK, Buttstedt A, Zebisch M, Schraml M, Hortschansky P, Knaus P, Schwarz E. 2009. The pro-form of BMP-2 interferes with BMP-2 signalling by competing with BMP-2 for IA receptor binding. FEBS J 276: 6386-6398
90. Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, ten Dijke P. 2010. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res 70: 4141-4150
91. Healey EG, Bishop B, Elegheert J, Bell CH, Padilla-Parra S, Siebold C. 2015. Repulsive guidance molecule is a structural bridge between neogenin and bone morphogenetic protein. Nat Struct Mol Biol 22: 458-465
92. Heinecke K, Seher A, Schmitz W, Mueller TD, Sebald W, Nickel J. 2009. Receptor oligomerization and beyond: A case study in bone morphogenetic proteins. BMC Biol 7: 59.
93. Hejnol A, Obst M, Stamatakis A, Ott M, Rouse GW, Edgecombe GD, Martinez P, Baguna J, Bailly X, Jondelius U, et al. 2009. Assessing the root of bilaterian animals with scalable phylogenomic methods. Proc Biol Sci 276: 4261-4270
94. Herpin A, Lelong C, Favrel P. 2004. Transforming growth factor-b-related proteins: An ancestral and widespread superfamily of cytokines in metazoans. Dev Comp Immunol 28: 461-485
95. Hinck AP, Archer SJ, Qian SW, Roberts AB, Sporn MB, Weatherbee JA, Tsang ML, Lucas R, Zhang BL, Wenker J, et al. 1996. Transforming growth factor b1: Threedimensional structure in solution and comparison with the X-ray structure of transforming growth factor b2. Biochemistry 35: 8517-8534
96. Hohenester E, Maurer P, Timpl R. 1997. Crystal structure of a pair of follistatin-like and EF-hand calcium-binding domains in BM-40. EMBO J 16: 3778-3786
97. Holdsworth G, Slocombe P, Doyle C, Sweeney B, Veverka V, Le Riche K, Franklin RJ, Compson J, Brookings D, Turner J, et al. 2012. Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors. J Biol Chem 287: 26464-26477
98. Holland ND, Holland LZ, Holland PW. 2015. Scenarios for the making of vertebrates. Nature 520: 450-455
99. Huang T, Schor SL, Hinck AP. 2014. Biological activity differences between TGF-β1 and TGF-β3 correlate with differences in the rigidity and arrangement of their component monomers. Biochemistry 53: 5737-5749
100. Huminiecki L, Goldovsky L, Freilich S, Moustakas A, Ouzounis C, Heldin CH. 2009. Emergence, development and diversification of the TGF-β signalling pathwaywithin the animal kingdom. BMC Evol Biol 9: 28.
101. Iemura S, Yamamoto TS, Takagi C, Uchiyama H, Natsume T, Shimasaki S, Sugino H, Ueno N. 1998. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci 95: 9337-9342.
102. Israel DI, Nove J, Kerns KM, Moutsatsos IK, Kaufman RJ. 1992. Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells. Growth Factors 7: 139-150
103. Israel DI, Nove J, Kerns KM, Kaufman RJ, Rosen V, Cox KA, Wozney JM. 1996. Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors 13: 291-300
104. Itasaki N, Jones CM, Mercurio S, Rowe A, Domingos PM, Smith JC, Krumlauf R. 2003. Wise, a context-dependent activator and inhibitor of Wnt signalling. Development 130: 4295-4305
105. Jeong H, Tombor B, Albert R, Oltvai ZN, Barabasi AL. 2000. The large-scale organization of metabolic networks. Nature 407: 651-654
106. Katoh K, Standley D. 2013. MAFFTmultiple sequence alignment software version 7: Improvements in performance and usability. Mol Biol Evol 30: 772-780
107. Kattamuri C, Luedeke DM, Nolan K, Rankin SA, Greis KD, Zorn AM, Thompson TB. 2012. Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers. J Mol Biol 424: 313-327
108. Ke J, Harikumar KG, Erice C, Chen C, Gu X, Wang L, Parker N, Cheng Z, Xu W, Williams BO, et al. 2013. Structure and function of Norrin in assembly and activation of a Frizzled 4-Lrp5/6 complex. Genes Dev 27: 2305-2319
109. Keller S, Nickel J, Zhang JL, Sebald W, Mueller TD. 2004. Molecular recognition of BMP-2 and BMP receptor IA. Nat Struct Mol Biol 11: 481-488
110. Kirkbride KC, Townsend TA, Bruinsma MW, Barnett JV, Blobe GC. 2008. Bone morphogenetic proteins signal through the transforming growth factor-b type III receptor. J Biol Chem 283: 7628-7637
111. Kirsch T, Sebald W, Dreyer MK. 2000. Crystal structure of the BMP-2-BRIA ectodomain complex. Nat Struct Biol 7: 492-496
112. Klages J, Kotzsch A, Coles M, Sebald W, Nickel J, Muller T, Kessler H. 2008. The solution structure of BMPR-IA reveals a local disorder-to-order transition upon BMP-2 binding. Biochemistry 47: 11930-11939
113. Klammert U, Mueller TD, Hellmann TV, Wuerzler KK, Kotzsch A, Schliermann A, Schmitz W, Kuebler AC, Sebald W, Nickel J. 2015. GDF-5 can act as a context-dependent BMP-2 antagonist. BMC Biol 13: 77.
114. Kotzsch A, Nickel J, Seher A, Heinecke K, van Geersdaele L, Herrmann T, Sebald W, Mueller TD. 2008. Structure analysis of bone morphogenetic protein-2 type I receptor complexes reveals a mechanism of receptor inactivation in juvenile polyposis syndrome. J Biol Chem 283: 5876-5887.
115. Kotzsch A, Nickel J, Seher A, Sebald W, Muller TD. 2009. Crystal structure analysis reveals a spring-loaded latch as molecular mechanism for GDF-5-type I receptor specificity. EMBO J 28: 937-947
116. Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, van Bezooijen RL, Hatsell S, Economides AN, Mueller TD, Lowik CW, et al. 2010. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 285: 41614-41626
117. Kumar TR. 2005. Too many follistatins: Racing inside and getting out of the cell. Endocrinology 146: 5048-5051
118. Kuns-Hashimoto R, Kuninger D, Nili M, Rotwein P. 2008. Selective binding of RGMc/hemojuvelin, a key protein in systemic iron metabolism, to BMP-2 and neogenin. Am J Physiol Cell Physiol 294: C994-C1003
119. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N. 2003. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278: 24113-24117
120. Lamarre J, Vasudevan J, Gonias SL. 1994. Plasmin cleaves betaglycan and releases a 60 kDa transforming growth factor-b complex from the cell surface. Biochem J 302: 199-205
121. Larrain J, Bachiller D, Lu B, Agius E, Piccolo S, De Robertis EM. 2000. BMP-binding modules in chordin: A model for signalling regulation in the extracellular space. Development 127: 821-830
122. Larrain J, Oelgeschlager M, Ketpura NI, Reversade B, Zakin L, De Robertis EM. 2001. Proteolytic cleavage of Chordin as a switch for the dual activities of Twisted gastrulation in BMP signaling. Development 128: 4439-4447
123. Lerch TF, Shimasaki S, Woodruff TK, Jardetzky TS. 2007. Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions. J Biol Chem 282: 15930-15939
124. Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM, Vale W. 2000. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 404: 411-414
125. Li S, Armstrong CM, Bertin N, Ge H, Milstein S, Boxem M, Vidalain PO, Han JD, Chesneau A, Hao T, et al. 2004. A map of the interactome network of the metazoan C. elegans. Science 303: 540-543
126. Li S, Shimono C, Norioka N, Nakano I, Okubo T, Yagi Y, Hayashi M, Sato Y, Fujisaki H, Hattori S, et al. 2010. Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity. J Biol Chem 285: 36645-36655
127. Liao WX, Moore RK, Otsuka F, Shimasaki S. 2003. Effect of intracellular interactions on the processing and secretion of bone morphogenetic protein-15 (BMP-15) and growth and differentiation factor-9. Implication of the aberrant ovarian phenotype of BMP-15 mutant sheep. J Biol Chem 278: 3713-3719
128. Lin SJ, Hu Y, Zhu J, Woodruff TK, Jardetzky TS. 2011. Structure of betaglycan zona pellucida (ZP)-C domain provides insights into ZP-mediated protein polymerization and TGF-β binding. Proc Natl Acad Sci 108: 5232-5236.
129. Lintern KB, Guidato S, Rowe A, Saldanha JW, Itasaki N. 2009. Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. J Biol Chem 284: 23159-23168
130. Little SC, Mullins MC. 2009. Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis. Nat Cell Biol 11: 637-643
131. Liu F, Ventura F, Doody J, Massague J. 1995. Human type II receptor for bone morphogenic proteins (BMPs): Extension of the two-kinase receptor model to the BMPs. Mol Cell Biol 15: 3479-3486
132. Lopez-Casillas F, Wrana JL, Massague J. 1993. Betaglycan presents ligand to the TGF-β signaling receptor. Cell 73: 1435-1444
133. Lowe CJ, Clarke DN, Medeiros DM, Rokhsar DS, Gerhart J. 2015. The deuterostome context of chordate origins. Nature 520: 456-465
134. Luyten FP, Cunningham NS, Ma S, Muthukumaran N, Hammonds RG, Nevins WB, Woods WI, Reddi AH. 1989. Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation. J Biol Chem 264: 13377-13380
135. Mace PD, Cutfield JF, Cutfield SM. 2006. High resolution structures of the bone morphogenetic protein type II receptor in two crystal forms: Implications for ligand binding. Biochem Biophys Res Commun 351: 831-838
136. Mahlawat P, Ilangovan U, Biswas T, Sun LZ, Hinck AP. 2012. Structure of the Alk1 extracellular domain and characterization of its bone morphogenetic protein (BMP) binding properties. Biochemistry 51: 6328-6341
137. Mangino M, Flex E, Digilio MC, Giannotti A, Dallapiccola B. 2002. Identification of a novel NOG gene mutation (P35S) in an Italian family with symphalangism. Hum Mutat 19: 308.
138. Marlow MS, Brown CB, Barnett JV, Krezel AM. 2003. Solution structure of the chick TGFb type II receptor ligand-binding domain. J Mol Biol 326: 989-997
139. Matsunaga E, Tauszig-Delamasure S, Monnier PP, Mueller BK, Strittmatter SM, Mehlen P, Chedotal A. 2004. RGM and its receptor neogenin regulate neuronal survival. Nat Cell Biol 6: 749-755
140. McLean S, Bhattacharya M, Di Guglielmo GM. 2013. barrestin2 interacts with TbRII to regulate Smad-dependent and Smad-independent signal transduction. Cell Signal 25: 319-331
141. McNatty KP, Juengel JL, Reader KL, Lun S, Myllymaa S, Lawrence SB, Western A, Meerasahib MF, Mottershead DG, Groome NP, et al. 2005. Bone morphogenetic protein 15 and growth differentiation factor 9 co-operate to regulate granulosa cell function. Reproduction 129: 473-480
142. Mendoza V, Vilchis-Landeros MM, Mendoza-Hernandez G, Huang T, Villarreal MM, Hinck AP, Lopez-Casillas F, Montiel JL. 2009. Betaglycan has two independent domains required for high affinity TGF-β binding: Proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor. Biochemistry 48: 11755-11765
143. Mi LZ, Brown CT, Gao Y, Tian Y, Le VQ, Walz T, Springer TA. 2015. Structure of bone morphogenetic protein 9 procomplex. Proc Natl Acad Sci 24: 3710-3715
144. Minchiotti G, Parisi S, Liguori G, Signore M, Lania G, Adamson ED, Lago CT, Persico MG. 2000. Membraneanchorage of Cripto protein by glycosylphosphatidylino-sitol and its distribution during early mouse development. Mech Dev 90: 133-142
145. Mittl PR, Priestle JP, Cox DA, McMaster G, Cerletti N, Grutter MG. 1996. The crystal structure of TGF-β 3 and comparison to TGF-β2: Implications for receptor binding. Protein Sci 5: 1261-1271
146. Miyazono K, Olofsson A, Colosetti P, Heldin CH. 1991. A role of the latent TGF-β1-binding protein in the assembly and secretion of TGF-β1. EMBOJ 10: 1091-1101
147. Monnier PP, Sierra A, Macchi P, Deitinghoff L, Andersen JS, Mann M, Flad M, Hornberger MR, Stahl B, Bonhoeffer F, et al. 2002. RGM is a repulsive guidance molecule for retinal axons. Nature 419: 392-395
148. Mottershead DG, Harrison CA, Mueller TD, Stanton PG, Gilchrist RB, McNatty KP. 2013. Growth differentiation factor 9:bone morphogenetic protein 15 (GDF9:BMP15) synergism and protein heterodimerization. Proc Natl Acad Sci 110: E2257.
149. Mottershead DG, Sugimura S, Al-Musawi SL, Li JJ, Richani D, White MA, Martin GA, Trotta AP, Ritter LJ, Shi J, et al. 2015. Cumulin, an oocyte-secreted heterodimer of the transforming growth factor-b family, is a potent activator of granulosa cells and improves oocyte quality. J Biol Chem 290: 24007-24020
150. Mueller TD. 2015. RGM co-receptors add complexity to BMP signaling. Nat Struct Mol Biol 22: 439-440
151. Muller BK, Jay DG, Bonhoeffer F. 1996. Chromophore-assisted laser inactivation of a repulsive axonal guidance molecule. Curr Biol 6: 1497-1502
152. Munger JS, Huang X, Kawakatsu H, Griffiths MJD, Dalton SL, Wu J, Pittet J-F, Kaminski N, Garat C, Matthay MA, et al. 1999. The integrin avb6 binds and activates latent TGFb1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell 96: 319-328
153. Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, Syro LV, Kovacs K, Lloyd RV. 2011. Endoglin (CD105): A review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res 31: 2283-2290
154. Nickel J, Kotzsch A, Sebald W, Mueller TD. 2005. A single residue of GDF-5 defines binding specificity to BMP receptor IB. J Mol Biol 349: 933-947
155. Nishimatsu S, Thomsen GH. 1998. Ventral mesoderm induction and patterning by bone morphogenetic protein heterodimers in Xenopus embryos. Mech Dev 74: 75-88
156. Nolan K, Thompson TB. 2014. The DAN family: Modulators of TGF-β signaling and beyond. Prot Sci 23: 999-1012.
157. Nolan K, Kattamuri C, Luedeke DM, Deng X, Jagpal A, Zhang F, Linhardt RJ, Kenny AP, Zorn AM, Thompson TB. 2013. Structure of protein related to Dan and Cerberus: Insights into the mechanism of bone morphogenetic protein antagonism. Structure 21: 1417-1429
158. Nolan K, Kattamuri C, Luedeke DM, Angerman EB, Rankin SA, Stevens ML, Zorn AM, Thompson TB. 2015. Structure of neuroblastoma suppressor of tumorigenicity 1 (NBL1): Insights for the functional variability across bone morphogenetic protein (BMP) antagonists. J Biol Chem 290: 4759-4771
159. O’Connor MB, Umulis D, Othmer HG, Blair SS. 2006. Shaping BMP morphogen gradients in the Drosophila embryo and pupal wing. Development 133: 183-193
160. Oelgeschlager M, Larrain J, Geissert D, De Robertis EM. 2000. The evolutionarily conserved BMP-binding protein Twisted gastrulation promotes BMP signalling. Nature 405: 757-763
161. O’Leary JM, Hamilton JM, Deane CM, Valeyev NV, Sandell LJ, Downing AK. 2004. Solution structure and dynamics of a prototypical chordin-like cysteine-rich repeat (von Willebrand Factor type C module) from collagen IIA. J Biol Chem 279: 53857-53866
162. Paine-Saunders S, Viviano BL, Economides AN, Saunders S. 2002. Heparan sulfate proteoglycans retain Noggin at the cell surface: A potential mechanism for shaping bone morphogenetic protein gradients. J Biol Chem 277: 2089-2096
163. Pang K, Ryan JF, Baxevanis AD, Martindale MQ. 2011. Evolution of the TGF-β signaling pathway and its potential role in the ctenophore, Mnemiopsis leidyi. PLoS ONE 6: e24152.
164. Pearce JJ, Penny G, Rossant J. 1999. A mouse cerberus/Danrelated gene family. Dev Biol 209: 98-110
165. Peng J, Li Q, Wigglesworth K, Rangarajan A, Kattamuri C, Peterson RT, Eppig JJ, Thompson TB, Matzuk MM.2013. Growth differentiation factor 9:bone morphogenetic protein 15 heterodimers are potent regulators of ovarian functions. Proc Natl Acad Sci 110: E776-E785
166. Piccolo S, Agius E, Lu B, Goodman S, Dale L, De Robertis EM. 1997. Cleavage of chordin by xolloid metalloprotease suggests a role for proteolytic processing in the regulation of Spemann organizer activity. Cell 91: 407-416.
167. Piccolo S, Agius E, Leyns L, Bhattacharyya S, Grunz H, Bouwmeester T, De Robertis EM. 1999. The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals. Nature 397: 707-710
168. Pietrzak WS, Woodell-May J, McDonald N. 2006. Assay of bone morphogenetic protein-2, -4, and-7 in human demineralized bone matrix. J Craniofac Surg 17: 84-90
169. Radaev S, Zou Z, Huang T, Lafer EM, Hinck AP, Sun PD. 2010. Ternary complex of transforming growth factor-b1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily. J Biol Chem 285: 14806-14814.
170. Rajagopalan S, Deitinghoff L, Davis D, Conrad S, Skutella T, Chedotal A, Mueller BK, Strittmatter SM. 2004. Neogenin mediates the action of repulsive guidance molecule. Nat Cell Biol 6: 756-762
171. Robertson IB, Rifkin DB. 2013. Unchaining the beast; insights from structural and evolutionary studies on TGFb secretion, sequestration, and activation. Cytokine Growth Factor Rev 24: 355-372
172. Roch GJ, Sherwood NM. 2014. Glycoprotein hormones and their receptors emerged at the origin of metazoans. Genome Biol Evol 5: 1466-1479
173. Rosa FM. 2002. Cripto, a multifunctional partner in signaling: Molecular forms and activities. Sci STKE 2002: e47.
174. Ross JJ, Shimmi O, Vilmos P, Petryk A, Kim H, Gaudenz K, Hermanson S, Ekker SC, O’Connor MB, Marsh JL. 2001. Twisted gastrulation is a conserved extracellular BMP antagonist. Nature 410: 479-483
175. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M, Ayivi-Guedehoussou N, et al. 2005. Towards a proteome-scale map of the human protein-protein interaction network. Nature 437: 1173-1178
176. Ruppert R, Hoffmann E, Sebald W. 1996. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 237: 295-302
177. Samad TA, Rebbapragada A, Bell E, Zhang Y, Sidis Y, Jeong SJ, Campagna JA, Perusini S, Fabrizio DA, Schneyer AL, et al. 2005. DRAGON, a bone morphogenetic protein coreceptor. J Biol Chem 280: 14122-14129
178. Sampath TK, Reddi AH. 1981. Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation. Proc Natl Acad Sci 78: 7599-7603
179. Sampath TK, Reddi AH. 1984. Distribution of bone inductive proteins in mineralized and demineralized extracellular matrix. Biochem Biophys Res Commun 119: 949-954.
180. Saremba S, Nickel J, Seher A, Kotzsch A, Sebald W, Mueller TD. 2008. Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand. FEBS J 275: 172-183
181. Sasai Y, Lu B, Steinbeisser H, Geissert D, Gont LK, De Robertis EM. 1994. Xenopus chordin: A novel dorsalizing factor activated by organizer-specific homeobox genes. Cell 79: 779-790
182. Scheufler C, Sebald W, Hulsmeyer M. 1999. Crystal structure of human bone morphogenetic protein-2 at 2.7 Å resolution. J Mol Biol 287: 103-115
183. Schlunegger MP, Grutter MG. 1992. An unusual feature revealed by the crystal structure at 2.2 Å resolution of human transforming growth factor-b2. Nature 358: 430-434
184. Schneyer A, Sidis Y, Xia Y, Saito S, del Re E, Lin HY, Keutmann H. 2004. Differential actions of follistatin and follistatin-like 3. Mol Cell Endocrinol 225: 25-28
185. Schneyer AL, Sidis Y, Gulati A, Sun JL, Keutmann H, Krasney PA. 2008. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin. Endocrinology 149: 4589-4595
186. Schreuder H, Liesum A, Pohl J, Kruse M, Koyama M. 2005. Crystal structure of recombinant human growth and differentiation factor 5: Evidence for interaction of the type I and type II receptor-binding sites. Biochem Biophys Res Commun 329: 1076-1086
187. Schwaerzer GK, Hiepen C, Schrewe H, Nickel J, Ploeger F, Sebald W, Mueller T, Knaus P. 2012.New insights into the molecular mechanism of multiple synostoses syndrome (SYNS): Mutation within the GDF5 knuckle epitope causes noggin-resistance. J Bone Miner Res 27: 429-442
188. Scott IC, Blitz IL, Pappano WN, Maas SA, Cho KW, Greenspan DS. 2001. Homologues of Twisted gastrulation are extracellular cofactors in antagonism of BMP signalling. Nature 410: 475-478
189. Seemann P, Brehm A, Konig J, Reissner C, Stricker S, Kuss P, Haupt J, Renninger S, Nickel J, Sebald W, et al. 2009. Mutations in GDF5 reveal a key residue mediating BMP inhibition by NOGGIN. PLoS Genet 5: e1000747.
190. Seidah NG, Prat A. 2012. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11: 367-383
191. Sengle G, Ono RN, Lyons KM, Bachinger HP, Sakai LY. 2008. A new model for growth factor activation: Type II receptors compete with the prodomain for BMP-7. J Mol Biol 381: 1025-1039
192. Sengle G, Ono RN, Sasaki T, Sakai LY. 2011. Prodomains of transforming growth factor b (TGFb) superfamily members specify different functions: Extracellular matrix interactions and growth factor bioavailability. J Biol Chem 286: 5087-5099
193. Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, Springer TA. 2011. Latent TGF-β structure and activation. Nature 474: 343-349
194. Shim A, Liu H, Focia P, Chen X, Lin P, He X. 2010. Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc Natl Acad Sci 107: 11307-11312
195. Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A. 2006. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology 147: 3586-3597
196. Smith WC, Harland RM. 1992. Expression cloning of noggin, a new dorsalizing factor localized to the Spemann organizer in Xenopus embryos. Cell 70: 829-840
197. Song K, Krause C, Shi S, Patterson M, Suto R, Grgurevic L, Vukicevic S, van Dinther M, Falb D, Ten Dijke P, et al. 2010. Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity. J Biol Chem 285: 12169-12180
198. Springer TA. 2014. vonWillebrand factor, Jedi knight of the bloodstream. Blood 124: 1412-1425
199. Stamler R, Keutmann HT, Sidis Y, Kattamuri C, Schneyer A, Thompson TB. 2008. The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity. J Biol Chem 283: 32831-32838
200. Stanley E, Biben C, Kotecha S, Fabri L, Tajbakhsh S, Wang CC, Hatzistavrou T, Roberts B, Drinkwater C, Lah M, et al. 1998. DAN is a secreted glycoprotein related to Xenopus cerberus. Mech Dev 77: 173-184
201. Stenvers KL, Tursky ML, Harder KW, Kountouri N, Amatayakul-Chantler S, Grail D, Small C, Weinberg RA, Sizeland AM, Zhu HJ. 2003. Heart and liver defects and reduced transforming growth factor b2 sensitivity in transforming growth factor b type III receptor-deficient embryos. Mol Cell Biol 23: 4371-4385
202. Suzuki A, Kaneko E, Maeda J, Ueno N. 1997. Mesoderm induction by BMP-4 and-7 heterodimers. Biochem Biophys Res Commun 232: 153-156
203. Tassew NG, Charish J, Seidah NG, Monnier PP. 2012. SKI-1 and Furin generate multiple RGMa fragments that regulate axonal growth. Dev Cell 22: 391-402
204. ten Dijke P, Yamashita H, Ichijo H, Franzen P, Laiho M, Miyazono K, Heldin CH. 1994a. Characterization of type I receptors for transforming growth factor-b and activin. Science 264: 101-104
205. ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevez M, Riddle DL, Ichijo H, Heldin CH, Miyazono K. 1994b. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem 269: 16985-16988
206. Thompson TB, Woodruff TK, Jardetzky TS. 2003. Structures of anActRIIB:activinAcomplex reveal a novel binding mode for TGF-β ligand:receptor interactions. EMBO J 22: 1555-1566
207. Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS. 2005. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell 9: 535-543
208. Tibaldi E, Arrigoni G, Martinez HM, Inagaki K, Shimasaki S, Pinna LA. 2010. Golgi apparatus casein kinase phosphorylates bioactive Ser-6 of bone morphogenetic protein 15 and growth and differentiation factor 9. FEBS Lett 584: 801-805
209. Tilak A, Nelsen SM, Kim HS, Donley N, McKnite A, Lee H, Christian JL. 2014. Simultaneous rather than ordered cleavage of two sites within the BMP4 prodomain leads to loss of ligand in mice. Development 141: 3062-3071
210. Tillet E, Bailly S. 2014. Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia. Front Genet 5: 456.
211. Townson SA, Martinez-Hackert E, Greppi C, Lowden P, Sako D, Liu J, Ucran JA, Liharska K, Underwood KW, Seehra J, et al. 2012. Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex. J Biol Chem 287: 27313-27325
212. Tsvetanova NG, Irannejad R, von Zastrow M. 2015. G protein-coupled receptor (GPCR) signaling via heterotrimeric G proteins from endosomes. J Biol Chem 290: 6689-6696
213. van Bezooijen RL, Roelen BA, Visser A, van derWee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW. 2004. Sclerostin is an osteocyteexpressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199: 805-814
214. van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, et al. 2007. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMPstimulated bone formation. J Bone Miner Res 22: 19-28
215. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, et al. 2009. Characterization of the structural features and interactions of sclerostin: Molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 284: 10890-10900
216. Walton KL, Makanji Y, Wilce MC, Chan KL, Robertson DM, Harrison CA. 2009. A common biosynthetic pathway governs the dimerization and secretion of inhibin and related transforming growth factor b (TGFb) ligands. J Biol Chem 284: 9311-9320
217. Wang X, Baloh RH, Milbrandt J, Garcia KC. 2006. Structure of artemin complexed with its receptor GFRa3: Convergent recognition of glial cell line-derived neurotrophic factors. Structure 14: 1083-1092
218. Wang R, Zhu J, Dong X, Shi M, Lu C, Springer TA. 2012. GARPregulates the bioavailability and activation of TGFb. Mol Biol Cell 23: 1129-1139
219. Wang S, Ma J, Peng J, Xu J. 2013. Protein structure alignment beyond spatial proximity. Sci Rep 3: 1448.
220. Watanabe K, Bianco C, Strizzi L, Hamada S, Mancino M, Bailly V, Mo W, Wen D, Miatkowski K, Gonzales M, et al. 2007. Growth factor induction of Cripto-1 shedding by glycosylphosphatidylinositol-phospholipase D and enhancement of endothelial cell migration. J Biol Chem 282: 31643-31655
221. Weber D, Kotzsch A, Nickel J, Harth S, Seher A, Mueller U, Sebald W, Mueller TD. 2007. A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor. BMC Struct Biol 7: 6.
222. Wei Z, Salmon RM, Upton PD, Morrell NW, Li W. 2014. Regulation of bone morphogenetic protein 9 (BMP9) by redox-dependent proteolysis. J Biol Chem 289: 31150-31159.
223. Weidauer SE, Schmieder P, Beerbaum M, Schmitz W, Oschkinat H, Mueller TD. 2009. NMR structure of the Wnt modulator protein Sclerostin. Biochem Biophys Res Commun 380: 160-165
224. Wiater E, Harrison CA, Lewis KA, Gray PC, Vale WW. 2006. Identification of distinct inhibin and transforming growth factor b-binding sites on betaglycan: Functional separation of betaglycan co-receptor actions. J Biol Chem 281: 17011-17022
225. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, et al. 2003. Osteocyte control of bone formation via sclerostin, a novel BMPantagonist. EMBO J 22: 6267-6276
226. Wipff PJ, Hinz B. 2008. Integrins and the activation of latent transforming growth factor b1—An intimate relationship. Eur J Cell Biol 87: 601-615
227. Wipff PJ, Rifkin DB, Meister JJ, Hinz B. 2007.Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix. J Cell Biol 179: 1311-1323
228. Wooderchak-Donahue WL, McDonald J, O’Fallon B, Upton PD, Li W, Roman BL, Young S, Plant P, Fulop GT, Langa C, et al. 2013. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am J Hum Genet 93: 530-537
229. Yeo C, Whitman M. 2001. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. Mol Cell 7: 949-957
230. Yin H, Yeh LC, Hinck AP, Lee JC. 2008. Characterization of ligand-binding properties of the human BMP type II receptor extracellular domain. J Mol Biol 378: 191-203
231. Yoon BH, Esquivies L, Ahn C, Gray PC, Ye SK, Kwiatkowski W, Choe S. 2014. An activin A/BMP2 chimera, AB204, displays bone-healing properties superior to those of BMP2. J Bone Miner Res 29: 1950-1959
232. Yoshinaga K, Obata H, Jurukovski V, Mazzieri R, Chen Y, Zilberberg L, Huso D, Melamed J, Prijatelj P, Todorovic V, et al. 2008. Perturbation of transforming growth factor (TGF)-b1 associationwith latent TGF-β binding protein yields inflammation and tumors. Proc Natl Acad Sci 105: 18758-18763
233. Zakin L, Metzinger CA, Chang EY, Coffinier C, De Robertis EM. 2008. Development of the vertebral morphogenetic field in the mouse: Interactions between crossveinless-2 and twisted gastrulation. Dev Biol 323: 6-18
234. Zakin L, Chang EY, Plouhinec JL, De Robertis EM. 2010. Crossveinless-2 is required for the relocalization of Chordin protein within the vertebral field in mouse embryos. Dev Biol 347: 204-215
235. Zhang JL, Huang Y, Qiu LY, Nickel J, Sebald W. 2007. von Willebrand factor type C domain-containing proteins regulate bone morphogenetic protein signaling through different recognition mechanisms. J Biol Chem 282: 20002-20014
236. Zhang JL, Qiu LY, Kotzsch A, Weidauer S, Patterson L, Hammerschmidt M, Sebald W, Mueller TD. 2008. Crystal structure analysis reveals howthe chordin family member crossveinless 2 blocks BMP-2 receptor binding. Dev Cell 14: 739-750
237. Zhang AS, Yang F, Wang J, Tsukamoto H, Enns CA. 2009. Hemojuvelin-neogenin interaction is required for bone morphogenic protein-4-induced hepcidin expression. J Biol Chem 284: 22580-22589
238. Zhang JL, Patterson LJ, Qiu LY, Graziussi D, Sebald W, Hammerschmidt M. 2010. Binding between Crossveinless-2 and Chordin von Willebrand factor type C domains promotes BMP signaling by blocking Chordin activity. PLoS ONE 5: e12846.
239. Zheng Y, Wang L, Zhang X, Zhang X, Gu Z, Wu G. 2012. BMP2/7 heterodimer can modulate all cellular events of the in vitro RANKL-mediated osteoclastogenesis, respectively, in different dose patterns. Tissue Eng Part A 18: 621-630
240. Zhou YF, Springer TA. 2014. Highly reinforced structure of a C-terminal dimerization domain in von Willebrand factor. Blood 123: 1785-1793
241. Zhu W, Kim J, Cheng C, Rawlins BA, Boachie-Adjei O, Crystal RG, Hidaka C. 2006. Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro. Bone 39: 61-71
242. Zimmerman LB, De Jesus-Escobar JM, Harland RM. 1996. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86: 599-606.
243. Zuniga JE, Ilangovan U, Mahlawat P, Hinck CS, Huang T, Groppe JC, McEwen DG, Hinck AP. 2011. The TbR-I prehelix extension is structurally ordered in the unbound form and its flanking prolines are essential for binding. J Mol Biol 412: 601-618